- Home
- STG vs ARTV Comparison
STG vs ARTV Comparison
Compare STG & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- ARTV
- Stock Information
- Founded
- STG 2003
- ARTV 2019
- Country
- STG China
- ARTV United States
- Employees
- STG N/A
- ARTV N/A
- Industry
- STG Other Consumer Services
- ARTV
- Sector
- STG Real Estate
- ARTV
- Exchange
- STG Nasdaq
- ARTV NYSE
- Market Cap
- STG 73.4M
- ARTV 87.7M
- IPO Year
- STG 2018
- ARTV 2024
- Fundamental
- Price
- STG $9.20
- ARTV $3.00
- Analyst Decision
- STG
- ARTV Strong Buy
- Analyst Count
- STG 0
- ARTV 8
- Target Price
- STG N/A
- ARTV $18.14
- AVG Volume (30 Days)
- STG 63.0K
- ARTV 262.4K
- Earning Date
- STG 08-14-2025
- ARTV 08-28-2025
- Dividend Yield
- STG N/A
- ARTV N/A
- EPS Growth
- STG N/A
- ARTV N/A
- EPS
- STG 3.09
- ARTV N/A
- Revenue
- STG $269,356,990.00
- ARTV N/A
- Revenue This Year
- STG N/A
- ARTV N/A
- Revenue Next Year
- STG N/A
- ARTV N/A
- P/E Ratio
- STG $3.20
- ARTV N/A
- Revenue Growth
- STG N/A
- ARTV N/A
- 52 Week Low
- STG $4.25
- ARTV $1.47
- 52 Week High
- STG $15.00
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- STG 50.13
- ARTV N/A
- Support Level
- STG $10.08
- ARTV N/A
- Resistance Level
- STG $11.50
- ARTV N/A
- Average True Range (ATR)
- STG 1.57
- ARTV 0.00
- MACD
- STG -0.28
- ARTV 0.00
- Stochastic Oscillator
- STG 0.85
- ARTV 0.00
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).